Małgorzata Poręba1, Paweł Gać2, Lidia Usnarska-Zubkiewicz3, Witold Pilecki1, Kazimierz Kuliczkowski3, Grzegorz Mazur4, Małgorzata Sobieszczańska5, Rafał Poręba4. 1. Department of Pathophysiology, Wroclaw Medical University, Wroclaw, Poland. 2. Department of Hygiene, Wroclaw Medical University, Wroclaw, Poland. 3. Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland. 4. Department of Internal Medicine, Occupational Diseases and Hypertension, Wroclaw Medical University, Wroclaw, Poland. 5. Department of Geriatrics, Wroclaw Medical University, Wroclaw, Poland.
Abstract
BACKGROUND: Hematopoietic stem cell transplantation (HSCT) is a widely used procedure in the treatment of malignant diseases, including blood neoplasms and has increased survival in hematological diseases. The aim of the study was to analyze parameters of 24-hr ECG monitoring in patients with selected blood neoplasms in whom the procedure of hematopoietic stem cell transplantation was performed. METHODS: The study group consisted of 64 adults diagnosed with hematologic cancer qualified for HSCT with the previous high dose chemotherapy (HDC). In all patients 24-hr Holter monitoring was carried out twice. First examination took place prior to the HSCT procedure, and the second after finishing the procedure of HSCT. RESULTS: The minimal and mean heart rate (HR min and HR max) from 24-hr ECG recording was statistically significantly higher after the transplantation in comparison with the first test. The number of premature ventricular complexes (PVCs) was higher in the test after HSCT. In the second examination there was significantly higher percentage of premature ventricular complexes, incidents of tachycardia, and Mobitz type 1 second degree atrioventricular block. In regression analysis, in a group of patients with blood neoplasms after HSCT and HDC, administration of cyclophosphamide, fludarabine and total body irradiation were independent risk factors for electrocardiographic abnormalities in 24-hr Holter monitoring, that is, the increase in HR min, HR mean and PVCs. CONCLUSION: In patients with blood neoplasms undergoing HSCT more electrocardiographic abnormalities may be found after this procedure in comparison with the 24-hr Holter monitoring before transplantation.
BACKGROUND: Hematopoietic stem cell transplantation (HSCT) is a widely used procedure in the treatment of malignant diseases, including blood neoplasms and has increased survival in hematological diseases. The aim of the study was to analyze parameters of 24-hr ECG monitoring in patients with selected blood neoplasms in whom the procedure of hematopoietic stem cell transplantation was performed. METHODS: The study group consisted of 64 adults diagnosed with hematologic cancer qualified for HSCT with the previous high dose chemotherapy (HDC). In all patients 24-hr Holter monitoring was carried out twice. First examination took place prior to the HSCT procedure, and the second after finishing the procedure of HSCT. RESULTS: The minimal and mean heart rate (HR min and HR max) from 24-hr ECG recording was statistically significantly higher after the transplantation in comparison with the first test. The number of premature ventricular complexes (PVCs) was higher in the test after HSCT. In the second examination there was significantly higher percentage of premature ventricular complexes, incidents of tachycardia, and Mobitz type 1 second degree atrioventricular block. In regression analysis, in a group of patients with blood neoplasms after HSCT and HDC, administration of cyclophosphamide, fludarabine and total body irradiation were independent risk factors for electrocardiographic abnormalities in 24-hr Holter monitoring, that is, the increase in HR min, HR mean and PVCs. CONCLUSION: In patients with blood neoplasms undergoing HSCT more electrocardiographic abnormalities may be found after this procedure in comparison with the 24-hr Holter monitoring before transplantation.
Authors: J D Hidalgo; R Krone; M W Rich; K Blum; D Adkins; M-Y Fan; R Brown; S Devine; T Graubert; W Blum; M Tomasson; L T Goodnough; R Vij; J DiPersio; H Khoury Journal: Bone Marrow Transplant Date: 2004-10 Impact factor: 5.483
Authors: G L Phillips; B Meisenberg; D E Reece; V R Adams; A Badros; J Brunner; R Fenton; J Filicko; D Grosso; G A Hale; D S Howard; V P Johnson; A Kniska; K W Marshall; R Nath; E Reed; A P Rapoport; N Takebe; D H Vesole; J L Wagner; N Flomenberg Journal: Biol Blood Marrow Transplant Date: 2004-07 Impact factor: 5.742
Authors: M Spriano; M Clavio; P Carrara; L Canepa; M Miglino; I Pierri; L Celesti; E Rossi; R Vimercati; R Bruni Journal: Haematologica Date: 1994 May-Jun Impact factor: 9.941
Authors: Jason F Goldberg; Emily J Peters; Elizabeth A Tolley; Mazal N Hagler; Vijaya M Joshi; Shelby E Wallace; Simonne S Nouer; Gary S Beasley; Hugo R Martinez; Kaitlin A Ryan; Mohammed A Absi; Jenny R Strelsin; Jeffrey A Towbin; Brandon M Triplett Journal: Bone Marrow Transplant Date: 2021-05-20 Impact factor: 5.483